These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15196814)

  • 41. HIV type 1 infection in lymphoid tissue: natural history and model systems.
    Kitchen SG; Zack JA
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S235-9. PubMed ID: 9814949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Model of B immunoblastic lymphomas in the Hu-PBL-SCID mice].
    Chen DQ; Bai LJ; Liu QF; Cui LX; He W; Ba DN
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Jun; 25(3):294-6. PubMed ID: 12905742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PHI-443: a novel noncontraceptive broad-spectrum anti-human immunodeficiency virus microbicide.
    D'Cruz OJ; Samuel P; Uckun FM
    Biol Reprod; 2004 Dec; 71(6):2037-47. PubMed ID: 15306558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV-1 pathogenesis and therapeutic intervention in the SCID-hu Thy/Liv mouse: a model for primary HIV-1 infection in the human thymus.
    Su L
    Rev Med Virol; 1997 Sep; 7(3):157-166. PubMed ID: 10398480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.
    Meuleman P; Leroux-Roels G
    Antiviral Res; 2008 Dec; 80(3):231-8. PubMed ID: 18706933
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel robust hepatitis C virus mouse efficacy model.
    Zhu Q; Oei Y; Mendel DB; Garrett EN; Patawaran MB; Hollenbach PW; Aukerman SL; Weiner AJ
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3260-8. PubMed ID: 17005803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Limitations of the human-PBL-SCID mouse model for vaginal transmission of HIV-1.
    D'Cruz OJ; Uckun FM
    Am J Reprod Immunol; 2007 May; 57(5):353-60. PubMed ID: 17430499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hydroxyurea under study.
    Posit Aware; 1995; ():5. PubMed ID: 11362569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative Pharmacokinetics of a Dual Inhibitor of HIV-1, NBD-14189, in Rats and Dogs with a Proof-of-Concept Evaluation of Antiviral Potency in SCID-hu Mouse Model.
    Stoddart CA; Curreli F; Horrigan S; Altieri A; Kurkin AV; Debnath AK
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A modified SCID mouse model of HIV infection with utility for testing anti-HIV therapies.
    Pincus SH; Fang H; Wilkinson RA; Olson WC; Marcotte TK
    AIDS Res Hum Retroviruses; 2003 Oct; 19(10):901-8. PubMed ID: 14585222
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The SCID-hu myeloma model.
    Epstein J; Yaccoby S
    Methods Mol Med; 2005; 113():183-90. PubMed ID: 15968103
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Usefulness of severe combined immunodeficiency (scid) and inbred mice for studies of cysticercosis and echinococcosis.
    Nakaya K; Mamuti W; Xiao N; Sato MO; Wandra T; Nakao M; Sako Y; Yamasaki H; Ishikawa Y; Craig PS; Schantz PM; Ito A
    Parasitol Int; 2006; 55 Suppl():S91-7. PubMed ID: 16338168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment.
    Witt KL; Tice RR; Wolfe GW; Bishop JB
    Environ Mol Mutagen; 2004; 44(4):321-8. PubMed ID: 15476197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner.
    Shih CC; Kaneshima H; Rabin L; Namikawa R; Sager P; McGowan J; McCune JM
    J Infect Dis; 1991 Mar; 163(3):625-7. PubMed ID: 1995734
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Development of HPV16 positive cervical cancer model in the hu-PBL-SCID mouse and its immunological features].
    Liang ZX; Cheng Q; Chen HZ; Xie X; Ye DF
    Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1465-9. PubMed ID: 15500747
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha.
    Wu W; Rochford R; Toomey L; Harrington W; Feuer G
    Leuk Res; 2005 May; 29(5):545-55. PubMed ID: 15755507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.
    Mayhew CN; Sumpter R; Inayat M; Cibull M; Phillips JD; Elford HL; Gallicchio VS
    Antiviral Res; 2005 Jan; 65(1):13-22. PubMed ID: 15652967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 2-deoxy-D-glucose as a potential drug against fusogenic viruses including HIV.
    Parris GE
    Med Hypotheses; 2008; 70(4):776-82. PubMed ID: 17920779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide, ISIS 5320.
    Stoddart CA; Rabin L; Hincenbergs M; Moreno M; Linquist-Stepps V; Leeds JM; Truong LA; Wyatt JR; Ecker DJ; McCune JM
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2113-5. PubMed ID: 9687417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.